Last reviewed · How we verify
NCT05308927
French Registry of Children Treated With Norditropin® for Short Stature Associated With Noonan Syndrome
trial testing Norditropin in Noonan Syndrome in 221 participants. Enrolling by invitation.
17 March 2028
Quick facts
| Lead sponsor | Novo Nordisk A/S |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 221 |
| Start date | 16 March 2022 |
| Primary completion | 17 March 2028 |
| Estimated completion | 17 March 2028 |
| Sites | 3 locations across France |
Drugs / interventions tested
- Norditropin — full drug profile →
Conditions studied
- Noonan Syndrome — all drugs for Noonan Syndrome →
Sponsor
Novo Nordisk A/S — full company profile →
Who can join
Eligibility, any sex, with Noonan Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a non-interventional registry of children treated with Norditropin® for short stature due to Noonan Syndrome (NS). This study aims to provide data on long-term growth evolution and safety of Norditropin® as well as Health Related Quality of Life (HRQoL) data. This registry will include the entirety of children treated with Norditropin® for short stature due to NS over the inclusion period. The decision to initiate treatment with commercially available Norditropin® is made by the patient/parents/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05308927
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Norditropin
Trials testing the same drug.
- NCT04513171 — Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children · Phase 2, PHASE3 · completed
- NCT03288103 — Growth Hormone Treatment in Patients With Aggrecan (ACAN) Deficiency · Phase 1, PHASE2 · completed
- NCT03075644 — A Trial to Evaluate the Safety of Once Weekly Dosing of Somapacitan (NNC0195-0092) and Daily Norditropin® FlexPro® for 5 · Phase 3 · completed
- NCT00663611 — Growth Hormone Administration and the Human Immune System · Phase 1 · completed
Other recruiting trials for Noonan Syndrome
Currently open trials in the same condition.
- NCT07464821 — National Multicentre Study on Lipid Profile in Noonan Syndrome and Related Disorders: Trends by Age, Gender and Genotype · recruiting
- NCT06555237 — MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies · Phase 2 · recruiting
- NCT05361811 — Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and F · NA · recruiting
- NCT05723835 — A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 · Phase 3 · active not recruiting
- NCT04888936 — Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies · recruiting
Other Novo Nordisk A/S trials
Trials by the same sponsor.
- NCT07357740 — A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes · Phase 2 · not yet recruiting
- NCT07282613 — A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adoles · Phase 3 · not yet recruiting
- NCT07357766 — A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight · Phase 3 · not yet recruiting
- NCT07564414 — A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obe · Phase 3 · not yet recruiting
- NCT07400107 — AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Exc · Phase 3 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05308927 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novo Nordisk A/S
- Last refreshed: 25 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05308927.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing